Liquid Biopsy · Cancer Monitoring
Advanced Cancer Monitoring for Earlier Detection & Peace of Mind
After treatment, uncertainty is normal. LIQOMICS liquid biopsy helps detect cancer recurrence earlier with a simple blood test, giving you and your doctor the clarity you deserve.
Post-Diagnosis Monitoring: This test is for patients already diagnosed with cancer and is not intended for general cancer screening.
Scientific & Clinical Partners
Trusted by Researchers, Clinicians, and Patients
Oncologist-Led
Founded by a hemato-oncologist who understands the daily challenges of patients and doctors.
Certified Laboratory
Our facility operates under strict RiliBÄK and ISO standards to ensure clinical precision.
Trusted by Oncologists Across Europe
Collaborating with leading oncologists across Europe to integrate precise molecular monitoring into individual patient care plans.
University-Validated Technology
Born from breakthrough research in Germany, our proprietary technology applies advanced molecular science to support earlier cancer recurrence detection.
After Treatment, One Question Remains: Am I Truly Cancer-Free?
The fear of cancer returning can be overwhelming. You may feel relieved treatment is over, yet anxious about what comes next. Traditional monitoring methods often detect changes only when they are already advanced, leaving you in a fog of uncertainty. You deserve clarity: early enough to act, gentle enough to live your life.
Our Liquid Biopsy: A New Era of Precision
LIQOMICS' advanced liquid biopsy technology offers a non-invasive way to detect signs of cancer through a simple blood test, providing your doctor with crucial insights.
- Early Detection of Recurrence
- Personalised Treatment Insights
- Non-Invasive Monitoring (simple blood test)
- Reduced Anxiety, Greater Peace of Mind
For you, this means fewer burdensome examinations, more precise information for your doctor, and a greater sense of control over your health.
Find the Right Monitoring
for Your Cancer Type
Note: Our tests are specifically designed for patients currently in treatment or follow-up care.
What are you monitoring?
Still not sure? Contact us for guidance ↓
LymphoVista
A specialised monitoring test for patients who have been treated for lymphoma, helping your doctor catch signs of return before symptoms appear.
Explore Lymphoma MonitoringCancerVista
For patients with solid tumours, giving your oncologist an earlier window into how your body is responding to treatment.
Explore Solid Tumour MonitoringNot Sure Yet?
If you're unsure which test is right for you, or if your specific situation isn't listed, please contact us directly. Our team is here to help guide you.
Contact Us DirectlyYour Partner in Lymphoma Monitoring
If you've been treated for lymphoma, LymphoVista helps your doctor catch signs of return before symptoms appear. This means less anxiety for you and more precise, timely decisions for your care.
- Earlier Detection Identifies signs of return before they become symptomatic, giving your doctor time to act.
- Personalised Insights Tailored information specific to your lymphoma type and treatment history.
- Non-Invasive & Safe All it takes is a simple blood test: no surgical biopsies or complex procedures.
- Peace of Mind A greater sense of control and reduced fear of recurrence between appointments.
Advanced Monitoring for Solid Tumours
For patients with solid tumours, CancerVista gives your oncologist an earlier window into how your body is responding to treatment: or whether the cancer is returning.
- Treatment Response Reveals how your body is responding, enabling your doctor to fine-tune your care plan.
- Comprehensive Analysis Detects circulating tumour DNA across a wide range of solid tumour types.
- Simple & Safe A blood test is a gentle alternative to invasive surgical biopsies.
- Empowering Information Understand your disease status with greater clarity and confidence.
Defining the Path to Early Insight
To understand your results, it helps to understand the two pillars of our technology:
cfDNA
Cell-Free DNA are microscopic fragments of genetic material shed by cancer cells into your bloodstream. We capture these "genetic footprints" to see cancer activity at a molecular level.
MRD
Minimal Residual Disease refers to traces of cancer remaining in the body after treatment. These traces are invisible to traditional scans but detectable through our analysis.
By catching these signals early, we help your medical team transition from reactive waiting to proactive monitoring, supporting earlier intervention in your care.
Your Path to Personalised Monitoring
Think of our technology as a high-precision early warning system. While traditional scans look for visible changes, we look for microscopic "genetic footprints" that cancer cells leave behind in your blood. By catching these signals long before they show up on a scan, we help your medical team act earlier, turning complex genomic analysis into a simple, clear roadmap for your ongoing care.
Talk to Your Doctor
Start the conversation. You and your oncologist decide together if our "early warning system" fits your care plan.
Simple Blood Draw
Just a routine check-up. No surgery or hospital stays: just a standard blood draw that takes only a few minutes.
Advanced Lab Analysis
Expert analysis in Germany. Our lab looks for tiny "genetic footprints" that are far too small for any scan to see.
Report for Your Doctor
Clear answers. Your doctor gets a straightforward report that helps them guide your treatment with more confidence.
What Does Your Result Mean For You?
What it means: No detectable circulating tumor DNA was found in your blood.
This is a reassuring sign that your treatment is working. Your oncologist can use this information to guide your follow-up care and potentially reduce the intensity of monitoring if clinically appropriate.
What it means: Detectable circulating tumor DNA was found in your blood.
This early molecular signal allows your oncologist to intervene before symptoms appear. It's an opportunity to adjust treatment or monitoring strategy at a clinically meaningful time, giving your team options. This is the power of early detection.
Why LIQOMICS Was Founded
Dr. Sven Borchmann · MD, Hematology & Oncology · University Hospital Cologne
LIQOMICS was born from a personal and clinical conviction: cancer patients deserve better than reactive monitoring. Dr. Sven Borchmann, our founder and a hemato-oncologist with decades of experience, witnessed firsthand the anxiety of post-treatment uncertainty. Patients asked, "Is my treatment working? Will my cancer come back?" And oncologists faced the frustration of detecting changes only when they were already advanced.
The solution became clear: leverage cutting-edge molecular science to detect disease signals months earlier than conventional methods. In 2019, LIQOMICS was founded in Cologne, rooted in University of Cologne research, with one mission: to transform cancer monitoring from reactive to proactive, giving patients and doctors the clarity they deserve.
Built by Oncologists Who Understand Your Uncertainty
Ultra-Sensitive Detection
We catch microscopic signals of cancer that traditional scans often miss.
Personalised Approach
Your test is built specifically for your body's unique genetic footprint.
Research-Driven Innovation
Born from breakthroughs at the University of Cologne, built on years of study.
Non-Invasive & Safe
No hospital stay or surgery required: just a routine, painless blood test.
Fast Turnaround
Quick answers to help you and your doctor make decisions without delay.
Made in Germany & EU
Proudly developed and tested in Germany under the highest quality standards.
Common Questions
About liquid biopsy and cancer monitoring for patients.
Prepare for Your Next Doctor's Visit
Download our Physician Conversation Guide. This detailed PDF includes clinical data, eligibility criteria, and a list of specific questions to help you and your oncologist decide if LIQOMICS is right for your care.
Thank you.
Check your inbox: your PDF guide will arrive in just a few minutes. We recommend bringing a printed copy or having it ready on your phone for your next appointment.